ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE | A090485 | AMNEAL PHARMACEUTICALS
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Senores Pharmaceuticals, Inc FDA-2026-P-5984 · 7 docket documents Senores Pharmaceuticals, Inc. filed a suitability petition requesting that the FDA determine whether their proposed drug product is suitable for abbreviated new drug application (ANDA) submission, seeking a favorable eligibility determination that would allow them to proceed with developing and subm | Suitability | 2026-05-27 | Open | Senores Pharmaceuticals, Inc |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.1056
per ea
Lowest NADAC/Unit
$0.1056
per ea
Brand NDCs
0
Generic NDCs
4
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 53746061701TRAMADOL-ACETAMINOPHEN 37.5-325 MG TAB | $0.1056 | EA | Generic | — | 2026-08-19 |
| 53746061705TRAMADOL-ACETAMINOPHEN 37.5-325 MG TAB | $0.1056 | EA | Generic | — | 2026-08-19 |
| 53746061710TRAMADOL-ACETAMINOPHEN 37.5-325 MG TAB | $0.1056 | EA | Generic | — | 2026-08-19 |
| 50268077415TRAMADOL-ACETAMINOPHEN 37.5-325 MG TAB | $0.1056 | EA | Generic | — | 2026-08-19 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.